Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polyglutamine (PolyQ) Diseases: Genetics to Treatments

1 May 2014

Abstract excerpt

The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, a total of nine polyQ disorders have been described: six spinocerebellar ataxias (SCA) types 1, 2, 6, 7, 17; Machado-Joseph disease (MJD/SCA3); Huntington's disease (HD); dentatorubral pallidoluysian atrophy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Neurogenetic and Muscular Disorders Research
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24816443
DOI: 10.3727/096368914x678454

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polyglutamine (PolyQ) Diseases: Genetics to TreatmentsPMID 24816443Read ↗

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of NeurodegenerationSemantic proximity Read ↗

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.Semantic proximity Read ↗

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense TherapiesSemantic proximity Read ↗

[The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].Semantic proximity Read ↗

Polyglutamine spinocerebellar ataxias - from genes to potential treatments.Semantic proximity Read ↗

Juvenile Huntington’s Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic DataSemantic proximity Read ↗

Juvenile Huntington’s Disease and Other PolyQ diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic DataSemantic proximity Read ↗

Challenges of the Polyglutamine Diseases: From Dysfunctional Neuronal Circuitries to Neuron-Specific CAG Repeat InstabilitySemantic proximity Read ↗

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disordersSemantic proximity Read ↗

Polyglutamine Diseases and Transport ProblemsSemantic proximity Read ↗

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesSemantic proximity Read ↗

The stress granule protein G3BP1 reduces the levels of polyglutamine proteins and alleviates spinocerebellar ataxia associated deficitsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.